Last reviewed · How we verify

NCT04287647

Transpyloric Stenting As a Predictor for G-POEM for Refractory Gastroparesis

Recruiting now NA Last updated 17 February 2025
What this trial tests

NA trial testing Transpyloric stent in Gastroparesis in 36 participants. Currently enrolling.

Timeline
15 May 2019
Primary endpoint
6 June 2026
6 June 2026

Quick facts

Lead sponsorNorthwestern University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment36
Start date15 May 2019
Primary completion6 June 2026
Estimated completion6 June 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Northwestern University

Who can join

18 and older, any sex, with Gastroparesis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective sham study to investigate the role of transpyloric stenting with lumen apposing metal stent (LAMS) as a predictor for clinical response to gastric per-oral endoscopic pyloromyotomy (GPOEM) for refractory gastroparesis. The study hypothesizes that clinical improvement with transpyloric stenting in patients with refractory gastroparesis is a predictor of subsequent clinical success of GPOEM.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Gastroparesis

Currently open trials in the same condition.

Other Northwestern University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04287647.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing